jame
walter
md
richard
g
wunderink
md
viral
pathogen
common
caus
sever
lower
respiratori
tract
infect
adult
abil
rapidli
accur
identifi
viral
infect
dramat
improv
slow
culturebas
techniqu
larg
replac
multiplex
highthroughput
system
given
advanc
reevalu
role
respiratori
viral
test
adult
present
lower
respiratori
tract
infect
import
articl
review
potenti
benefit
test
provid
overview
commonli
use
diagnost
techniqu
consid
whether
current
evid
support
routin
test
lower
respiratori
tract
infect
lrti
encompass
rang
infect
acut
bronchiti
bronchiol
pneumonia
lrti
major
caus
morbid
mortal
adult
unit
state
billion
dollar
spent
annual
diagnosi
treatment
lrti
virus
frequent
identifi
pathogen
sever
communityacquir
respiratori
infect
diagnost
test
respiratori
virus
dramat
improv
last
sever
decad
slow
culturebas
techniqu
given
way
rapid
multiplex
highthroughput
system
backdrop
clinician
must
decid
test
respiratori
viral
pathogen
test
improv
antimicrobi
stewardship
facilit
earli
initi
antivir
therapi
mere
identifi
pathogen
uncertain
clinic
signific
increas
healthcar
cost
goal
present
review
answer
question
focus
specif
adult
hospit
suspect
lrti
decis
pursu
respiratori
viral
test
children
cover
elsewher
rational
test
merit
respiratori
viral
test
must
consid
context
recent
chang
epidemiolog
manag
sever
lrti
bacteria
tradit
view
domin
pathogen
sever
lrti
inde
rate
streptococcu
pneumonia
infect
patient
communityacquir
pneumonia
cap
frequent
approach
histor
studi
sever
factor
alter
paradigm
introduct
sevenval
pneumococc
conjug
vaccin
children
follow
conjug
vaccin
markedli
reduc
rate
sever
pneumococc
infect
even
adult
declin
rate
cigarett
smoke
one
greatest
risk
factor
pneumococc
infect
immunocompet
adult
reduc
incid
invas
pneumococc
diseas
final
age
popul
result
everincreas
number
individu
particularli
suscept
sever
viral
infect
elderli
time
like
develop
viral
pneumonia
younger
adult
experi
substanti
higher
morbid
mortal
viral
infect
illustr
trend
center
diseas
control
prevent
cdc
etiolog
pneumonia
commun
epic
studi
populationbas
surveil
studi
etiolog
cap
rigor
investig
adult
patient
detect
bacteri
pathogen
patient
infect
pneumonia
chang
lrti
epidemiolog
accompani
mark
improv
abil
detect
respiratori
viral
pathogen
clinic
practic
slow
laborintens
culturebas
techniqu
larg
replac
increasingli
sensit
diagnost
system
pair
nucleic
acid
amplif
multiplex
technolog
allow
multipl
virus
test
singl
sampl
discuss
later
detail
number
studi
leverag
advanc
diagnost
techniqu
better
character
preval
viral
infect
patient
hospit
lrti
cdc
epic
studi
patient
evid
viral
infect
rhinoviru
frequent
identifi
pathogen
overal
found
patient
result
mirror
find
metaanalysi
report
combin
incid
respiratori
virus
hospit
patient
cap
virus
seem
common
patient
admit
icu
fig
south
korean
studi
patient
pneumonia
admit
icu
viral
pathogen
identifi
rhinoviru
studi
icu
patient
report
viral
infect
rate
recognit
viral
pathogen
common
caus
sever
lrti
come
time
innov
approach
curb
antimicrobi
use
urgent
need
antibiot
overus
major
driver
antimicrobi
resist
rate
infect
drugresist
pathogen
frequent
exceed
sever
hospitalacquir
pneumonia
rais
concern
whole
class
antibiot
may
soon
prove
obsolet
respiratori
viral
test
offer
potenti
way
forward
sever
lrti
increasingli
viral
ill
perhap
leverag
improv
diagnost
tool
rapidli
identifi
larg
number
patient
antibiot
unnecessari
consid
clinic
impact
respiratori
viral
test
import
review
variou
way
virus
identifi
clinic
practic
numer
techniqu
current
avail
includ
everincreas
number
multiplex
molecular
assay
sheer
number
avail
test
modal
disori
practic
clinician
modal
strength
limit
test
characterist
although
comprehens
summari
diagnost
techniqu
beyond
scope
present
review
section
provid
gener
overview
commonli
use
test
platform
serolog
test
current
limit
role
diagnosi
viral
infect
acut
ill
patient
pathogenspecif
antibodi
titer
check
acut
convalesc
phase
ill
least
fourfold
increas
antibodi
level
view
diagnost
recent
infect
requir
test
week
follow
acut
ill
preclud
use
techniqu
guid
realtim
patient
care
addit
serolog
test
infrequ
use
includ
complement
fixat
hemagglutin
inhibit
assay
convent
tube
cultur
tube
cultur
tradit
consid
gold
standard
diagnosi
viral
infect
techniqu
clinic
specimen
ad
tube
contain
cell
suscept
specif
viru
span
sever
week
microscopi
use
examin
cell
characterist
cytopath
effect
indic
infect
confirm
immunofluoresc
stain
approach
multipl
limit
viral
cultur
slow
laborintens
make
poorli
suit
guid
manag
acut
ill
patient
numer
clinic
relev
respiratori
virus
respiratori
syncyti
viru
rsv
human
metapneumoviru
proven
uniqu
difficult
isol
cultur
final
convent
cultur
diagnosi
may
particularli
limit
older
adult
develop
infect
despit
low
viral
burden
develop
shellvial
cultur
techniqu
reduc
turnaround
time
culturebas
test
shellvial
cultur
perform
inocul
monolay
suscept
cell
grown
cover
slip
clinic
specimen
shellvial
tube
centrifug
promot
viral
infect
cellular
monolay
depend
viru
studi
confirmatori
stain
fluoresc
monoclon
antibodi
perform
follow
incub
period
day
improv
process
time
shellvial
cultur
similar
limit
tradit
cultur
techniqu
numer
rapid
antigen
detect
kit
commerci
avail
produc
test
result
min
kit
typic
base
either
immunofluoresc
antibodi
test
immunochromatograph
assay
although
quick
turnaround
time
appeal
widespread
adopt
kit
adult
limit
poor
sensit
polymeras
chain
reaction
nucleic
acid
amplif
use
polymeras
chain
reaction
pcr
revolution
detect
respiratori
viral
pathogen
develop
pcr
allow
exponenti
amplif
target
dna
sequenc
sampl
place
special
heat
block
call
thermocycl
cycl
three
temperaturedepend
step
denatur
anneal
elong
high
heat
z
c
initi
use
separ
doublestrand
dna
temperatur
lower
facilit
anneal
singlestrand
oligonucleotid
primer
complementari
dna
templat
final
step
temperatur
rais
approxim
c
allow
heatresist
dna
polymeras
catalyz
synthesi
new
dna
strand
pcrbase
test
offer
appeal
test
characterist
sensit
specif
frequent
approach
result
avail
matter
hour
facilit
rapid
pathogen
detect
newli
admit
patient
current
platform
obviat
need
skill
technician
basic
laboratori
personnel
howev
pcr
test
typic
expens
tradit
techniqu
addit
result
pcr
larg
qualit
thu
provid
limit
insight
pathogen
load
particular
viru
final
given
exquisit
sensit
pcrbase
test
may
frequent
detect
chronic
colon
lowlevel
viral
shed
follow
previou
infect
make
difficult
determin
clinic
relev
posit
test
result
reversetranscriptas
pcr
rtpcr
allow
rna
rather
dna
serv
start
materi
pcr
technolog
particularli
import
studi
lrti
given
number
rna
virus
implic
lrti
eg
rhinoviru
rsv
human
metapneumoviru
rtpcr
revers
transcriptas
use
synthes
complementari
dna
isol
rna
complementari
dna
undergo
pcr
amplif
describ
earlier
either
tube
part
twostep
process
realtim
pcr
technolog
allow
dna
amplif
quantifi
follow
pcr
cycl
goal
accomplish
use
fluoresc
dnabind
dye
whose
signal
intens
expos
energi
sourc
reflect
amount
amplifi
dna
mani
differ
probe
current
avail
includ
one
bind
nonselect
doublestrand
dna
eg
sybr
sequencespecif
hydrolysi
probe
eg
taqman
fluoresc
cleav
dna
polymeras
quantit
pcr
technolog
appli
either
tradit
pcr
rtpcr
platform
standard
pcr
quantit
realtim
pcr
highli
sensit
specif
addit
abil
provid
quantit
inform
pathogen
burden
may
help
distinguish
viral
carriag
true
infect
respiratori
viral
test
commonli
occur
multiplex
platform
mean
multipl
analyt
test
singl
sampl
exampl
respiratori
multi
well
system
rgene
assay
argen
biomerioux
simultan
test
respiratori
pathogen
multiplex
platform
often
highthroughput
signifi
multipl
sampl
depend
manufactur
process
singl
run
system
appeal
multipl
patient
sampl
quickli
test
clinic
relev
pathogen
facilit
rapid
diagnosi
identif
polymicrobi
infect
multiplex
system
vari
degre
autom
throughput
process
speed
cost
abil
produc
quantit
result
tabl
clinician
particular
note
platform
test
slightli
differ
group
viral
pathogen
addit
import
viral
caus
pulmonari
diseas
includ
varicellazost
viru
herp
simplex
viru
hantaviru
middl
east
respiratori
syndrom
coronaviru
cover
list
pcr
platform
therefor
requir
separ
test
mani
commerci
avail
platform
pair
multiplex
pcr
hybrid
amplifi
product
onto
microarray
often
read
proprietari
analyz
exampl
approach
includ
infin
autogenom
system
sampl
process
larg
autom
luminex
platform
use
liquidphas
beadbas
array
highthroughput
multiplex
detect
pathogen
simultan
technolog
incorpor
number
commerci
avail
kit
includ
resplex
assay
qiagen
xtag
respiratori
viral
panel
luminex
molecular
diagnost
multiplex
pcr
also
pair
mass
spectrometri
plexid
abbott
molecular
hybrid
gold
nanoparticleconjug
captur
probe
verigen
nanospher
melt
curv
analysi
filmarray
idaho
technolog
one
downsid
multiplex
pcr
test
reaction
condit
may
optim
specif
analyt
potenti
advers
affect
sensit
number
advanc
molecular
assay
mani
occur
isotherm
condit
current
develop
isotherm
amplif
obviat
need
thermocycl
offer
rapid
process
time
test
method
describ
lack
consist
diagnost
gold
standard
confound
attempt
determin
platform
true
test
characterist
exampl
studi
describ
sensit
specif
pcrbase
platform
often
defin
true
posit
viru
detect
least
two
pcr
assay
perform
convent
detect
techniqu
frequent
use
pcr
test
diagnost
standard
evalu
studi
respiratori
viral
test
clinician
cogniz
refer
standard
defin
respiratori
viral
test
ideal
incorpor
routin
care
improv
patient
outcom
scenario
might
occur
reduct
antibiot
exposur
rapid
initi
discontinu
antivir
therapi
avoid
unnecessari
diagnost
test
effect
use
respiratori
isol
room
clinic
efficaci
respiratori
viral
test
best
studi
children
small
pediatr
studi
respiratori
viral
test
found
reduc
exposur
antibiot
increas
administr
antivir
therapi
reduc
diagnost
test
reduc
time
patient
spend
isol
adult
respiratori
viral
test
inconsist
associ
improv
outcom
multipl
observ
studi
patient
influenza
infect
found
respiratori
viral
test
infrequ
alter
manag
singlecent
retrospect
review
adult
admit
respiratori
tract
infect
secondari
influenza
continu
antimicrobi
therapi
despit
posit
influenza
test
result
neg
bacteri
cultur
group
longer
hospit
length
stay
higher
hospit
cost
compar
patient
antibiot
stop
whether
advers
outcom
repres
direct
effect
continu
antibiot
result
appropri
antibiot
use
addit
diagnosi
influenza
associ
reduct
antibiot
durat
falsey
et
al
find
patient
posit
rapid
influenza
test
result
less
like
receiv
antibiot
vs
p
like
receiv
antivir
therapi
vs
p
patient
whose
rapid
test
result
neg
howev
differ
total
day
antibiot
therapi
group
found
lowrisk
patient
posit
rapid
viral
test
result
continu
receiv
antibiot
studi
need
clearli
determin
impact
influenza
test
antibiot
discontinu
addit
although
influenza
test
routin
increas
use
antivir
therapi
effect
like
depend
relationship
test
start
influenza
season
local
manag
approach
peak
influenza
season
institut
empir
antivir
therapi
routin
prescrib
neg
influenza
test
result
may
significantli
decreas
antivir
use
convers
viral
test
may
increas
use
antiinfluenza
medic
empir
antivir
therapi
rare
use
test
studi
earli
influenza
season
viral
ill
common
result
similarli
discourag
studi
patient
infect
viral
pathogen
larg
multiyear
review
admiss
singl
center
canada
multiplex
viral
test
associ
reduct
antibiot
therapi
time
spent
isol
room
similarli
review
patient
respiratori
tract
infect
viral
pathogen
identifi
use
quantit
realtim
pcr
antibiot
therapi
stop
follow
viral
test
includ
patient
normal
chest
imag
final
pcr
test
cohort
elderli
patient
admit
respiratori
infect
fail
reduc
antibiot
durat
hospit
length
stay
util
respiratori
viral
test
studi
sever
random
trial
multicent
trial
netherland
newli
admit
patient
receiv
antibiot
lrti
random
receiv
standard
care
viral
test
accord
multiplex
pcr
although
use
pcr
doubl
number
patient
identifi
pathogen
increas
hospit
cost
without
reduc
antibiot
use
diagnost
procedur
durat
hospit
stay
branch
et
al
random
patient
admit
lrti
receiv
either
standard
care
includ
use
influenzarsv
duplex
pcr
measur
procalcitonin
pct
pair
test
throat
nasal
swab
virus
use
multiplex
pcr
initi
antimicrobi
therapi
discourag
pct
valu
ngml
sixtythre
patient
intervent
arm
posit
pcr
wherea
patient
control
arm
posit
viral
test
result
although
differ
overal
antibiot
use
two
arm
found
subgroup
patient
low
pct
posit
viral
pcr
less
like
receiv
antibiot
discharg
vs
p
recent
publish
routin
molecular
pointofcar
test
respiratori
virus
adult
present
hospit
acut
respiratori
ill
respoc
studi
largest
trial
date
investig
abil
respiratori
viral
test
reduc
antibiot
exposur
singlecent
studi
adult
acut
respiratori
infect
recruit
ed
shortstay
acut
medic
unit
patient
control
arm
underw
standard
diagnost
test
includ
option
use
laboratorybas
pcr
test
five
respiratori
virus
patient
intervent
arm
nasal
throat
swab
test
multiplex
pcr
platform
locat
unit
total
patient
intervent
arm
viru
detect
influenza
rhinoviru
enteroviru
common
pathogen
identifi
patient
control
arm
underw
pcr
test
patient
found
viral
infect
turnaround
time
significantli
faster
intervent
arm
vs
h
p
although
differ
proport
patient
treat
antibiot
durat
antibiot
therapi
found
patient
intervent
arm
like
receiv
singl
dose
antibiot
vs
p
receiv
antibiot
h
vs
p
patient
influenza
infect
intervent
arm
like
receiv
neuraminidas
inhibitor
vs
p
place
respiratori
isol
quickli
vs
day
p
post
hoc
analysi
focus
patient
random
treatment
administr
antibiot
significantli
fewer
patient
intervent
arm
receiv
antibiot
therapi
vs
p
despit
remark
advanc
abil
detect
respiratori
viral
pathogen
test
inconsist
affect
antibiot
use
import
patient
outcom
sever
consider
deserv
mention
clinic
implic
posit
respiratori
viral
test
remain
sourc
debat
although
patient
intervent
arm
trial
may
receiv
expediti
comprehens
test
concurr
use
pcrbase
platform
patient
receiv
usual
care
make
identifi
signific
differ
outcom
challeng
focus
intervent
reduc
overus
given
pervas
recalcitr
natur
antibiot
overus
multifacet
approach
sure
requir
effect
solv
problem
agre
recommend
infecti
diseas
societi
america
rapid
respiratori
viral
test
use
help
reduc
unnecessari
antibiot
administr
adult
admit
sever
chestjournalorg
lrti
clinician
educ
regard
test
characterist
diagnost
platform
avail
within
institut
import
addit
test
implement
part
multidisciplinari
longitudin
antimicrobi
stewardship
program
report
small
studi
benefici
find
help
pair
respiratori
viral
test
measur
pct
biomark
shown
reduc
antibiot
administr
patient
present
respiratori
infect
even
patient
requir
admiss
icu
routin
discontinu
antibiot
therapi
pct
low
viral
pathogen
identifi
especi
test
perform
sampl
collect
lower
respiratori
tract
pathogen
noninfluenza
virus
remain
sourc
debat
rhinoviru
probabl
cite
exampl
rhinoviru
clearli
caus
pneumonia
children
viremia
detect
pleural
fluid
support
pathogen
data
adult
less
establish
view
compel
evid
suggest
virus
inde
caus
sever
diseas
initi
specif
antivir
therapi
influenza
adenoviru
critic
ill
patient
discontinu
empir
antiinfluenza
treatment
peak
season
also
guid
use
multiplex
viral
detect
emerg
specif
treatment
option
rsv
virus
influenc
clinic
benefit
respiratori
viral
test
robust
costeffect
data
need
guid
clinician
health
system
multiplex
pcr
test
implement
although
small
studi
suggest
use
multiplex
pcr
platform
reduc
cost
simplifi
laboratori
workflow
analysi
highli
depend
platform
use
baselin
oper
expens
competit
newer
technolog
like
result
cost
save
ultim
unequivoc
costeffect
depend
abil
leverag
multiplex
pcr
test
reduc
antibiot
exposur
hospit
length
stay
major
challeng
remain
larg
number
patient
admit
sever
lrti
pathogen
never
identifi
cdc
epic
studi
pathogen
identifi
patient
despit
diagnost
test
exceed
usual
practic
advanc
abil
better
phenotyp
patient
would
profound
implic
antimicrobi
stewardship
effort
clinic
trial
enrol
virus
common
caus
sever
lrti
adult
multiplex
highthroughput
diagnost
platform
allow
clinician
identifi
viral
pathogen
unpreced
speed
accuraci
although
respiratori
viral
test
yet
shown
convincingli
improv
patient
outcom
random
trial
hold
tremend
promis
tool
aid
rapid
diagnosi
improv
antimicrobi
stewardship
patient
sever
lrti
